Germany has a historical reputation as being a global leader in the pharmaceutical industry, being the headquarters of many global stalwarts such as Bayer, BASF, STADA, etc. The German pharmaceutical industry enjoys stability and therefore, it comes as no surprise that the generic drugs sector in Germany has also had a stable growth in recent years. Generic medicines contribute significantly to the German drug supply and the government has been making all efforts to further boost this sector with attractive pricing and innovations. In fact, in 2015, the volume share of generic drugs in Germany was over 75%, much higher than the share in European countries.
In 2016, the German generics sector comfortably crossed revenues of USD 8 billion and is expected to reach a value of nearly USD 9.5 billion by the end of 2021. As many generic drugs come off patent, the German generic industry is poised to take advantage of this situation and post further growth in coming years.
Aruvian Research presents Analyzing Generics Market in Germany 2017 – a comprehensive coverage of the German generic drugs market. Beginning with a sectional description on the global generic industry, the report looks at an overview of the industry, an analysis of the market volume and value, industry segmentation and an industry forecast.
Moving on, we analyze the Generics Industry in Europe through the same parameters.
The Generics Industry in Germany is analyzed through an industry overview which spans the data from 2012 till 2021. An analysis of the industry's value and volume data is included along with an industry segmentation by geography. Industry forecast of the industry is also included.
We also include a Porter’s Five Forces analysis of the German Generics Industry. Generics pricing and reimbursement situation in Germany and trends and challenges facing the industry are analyzed.
Analysis of the major industry players in the German generics market are analyzed through an analysis of their business segments, a financial analysis and a SWOT analysis. Players analyzed include STADA, Mylan, Sandoz International, Teva Pharmaceutical Industries and others.
This research report helps you get an insider’s look at the German generic industry and helps you understand what the future holds for the industry. Regulatory framework, pricing and reimbursement scenarios, comparison of the German market with its regional counterparts, all these data points makes this report an essential resource for analytical purposes.